A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects with MPS-IH Compared with Standard of Care with Allogeneic HSCT
Summary
- Eligibility
- for people ages up to 30 months (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Sandhya Kharbanda
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Sandhya Kharbanda
Dr. Sandhya Kharbanda is a specialist in pediatric blood disorders and stem cell transplantation, and the medical director of the pediatric blood and marrow transplant program at UCSF Benioff Children's Hospital San Francisco.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Orchard Therapeutics
- ID
- NCT06149403
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 40 study participants
- Last Updated